Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00120861 · ClinicalTrials.gov registry record · Phase 2
Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00120861 is a Phase 2 study that has completed, run by Merck Sharp & Dohme.
The verdict
NCT00120861, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
This study is being conducted to compare the safety, effectiveness and tolerance of valopicitabine (NM283) when used alone and when valopicitabine is used together with pegylated interferon in hepatitis C treatment failure patients. These results will be compared against the results of treatment with pegylated interferon plus ribavirin, the current standard therapy for treatment of hepatitis C viral infection.
Interventions
- DRUG ribavirin
- DRUG valopicitabine
- DRUG pegylated interferon
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00120861
The ClinicalTrials.gov registry entry for NCT00120861 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ribavirin is the first listed.
NCT00120861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00120861 about?
NCT00120861 is a clinical study titled "Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy". This study is being conducted to compare the safety, effectiveness and tolerance of valopicitabine (NM283) when used alone and when valopicitabine is used together with pegylated interferon in hepatitis C treatment failure patients. These results will be compared against the results of treatment wit...
What is the current status of trial NCT00120861?
This trial is currently completed. It is a Phase 2 study. The study started on 2005-01.
What interventions are being tested in trial NCT00120861?
The interventions under investigation include: ribavirin (DRUG), valopicitabine (DRUG), pegylated interferon (DRUG).
Who is sponsoring clinical trial NCT00120861?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.